Sterlin Jones, OD
Optometrist · Atlanta, GANPI 1770136558
Payments from drug & device makers
Across 90 payments — averaging $49.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$989
- Johnson & Johnson Vision Care, Inc.$633
- Bausch & Lomb Americas Inc.$499
- Sun Pharmaceutical Industries Inc.$493
- Glaukos Corporation$396
- Bausch & Lomb, A Division Of Bausch Health US, LLC$380
- plus $1K from 11 others
What the payments were for
- Food & beverage$4,31197%
- Entertainment$1523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 19 | $989 |
| Johnson & Johnson Vision Care, Inc. | 13 | $633 |
| Bausch & Lomb Americas Inc. | 9 | $499 |
| Sun Pharmaceutical Industries Inc. | 10 | $493 |
| Glaukos Corporation | 4 | $396 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $380 |
| Alcon | 8 | $315 |
| Novartis | 3 | $170 |
| AbbVie(2 entities) | 4 | $156 |
| Optos, Inc. | 3 | $152 |
| Eyevance Pharmaceuticals LLC | 1 | $110 |
| Oyster Point Pharma, Inc. | 3 | $61 |
| Tarsus Pharmaceuticals, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Amgen | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $18 |
| LKC Technologies, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$354
- Clariti Contact Lens$306
- KXL System$238
- Photrexa$238
- PANORAMIC OPHTHALMOSCOPE$214
- OCT OPHTHALMOSCOPE$214
- iStent inject W$138
- INFUSE$124
- TRYPTYR$123
- ULTRA MULTIFOCAL TORIC$116
- PROLENSA$112
- XIIDRA$111
- FreshKote Preservative free Lubricant Eye Drops$110
- NFC-700$107
- MyDay Contact Lens$106
How this compares
$4,463 in reported general payments places this provider in the 85th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 154 | $99,339 |
| RestasisCyclosporine | 25 | $37,932 |
| XiidraLifitegrast | 18 | $17,966 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $16,689 |
| TyrvayaVarenicline Tartrate | 19 | $16,645 |
| CequaCyclosporine | 15 | $15,224 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $15,018 |
| Restasis MultidoseCyclosporine | 14 | $8,801 |
| Alphagan PBrimonidine Tartrate | 16 | $6,714 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $4,035 |
| Latanoprost | 328 | $3,088 |
| Prednisolone Acetate | 24 | $822 |
| Timolol Maleate | 78 | $657 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $607 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 55 | $583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Restasis Multidose, Alphagan P | $156 | $169,476242 claims |
| Bausch & Lomb Americas Inc.Xiidra | $499 | $17,96618 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $61 | $16,64519 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $493 | $15,22415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Atlanta
- Joshua JohnstonAtlanta$997K
- Katherine WooAtlanta$336K
- Stephanie RossAtlanta$283K
- Amber ZaunbrecherAtlanta$99K
- Emily LoveAtlanta$35K
- Carla AndersonAtlanta$29K
- Sarah FlanaganAtlanta$21K
- Anisha HajiAtlanta$19K
- Anar MauryaAtlanta$18K
- Jonathan ChenAtlanta$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.